proteins of the axonal cytoskeleton, belonging to the IV class of intermediate filaments that, according to their molecular weight, are classified into neurofilament heavy chain (NF-H, ≈200 kDa), neurofilament medium chain (NF-M, ≈145 kDa), and NF-L (≈68 kDa). All NF proteins are formed by a central α-helical rod region, a variable N-terminal domain, and a C-terminal tail highly variable in length. [3,4] NF monomers form parallel heterodimers through the association of the central rod region. Then, two dimers form an antiparallel tetramer, and eight tetramers associate in a cylindrical structure, which is the minimal repetitive unit of the neurofilament. Together with microfilaments (≈6-8 nm) and microtubules (≈24 nm), neurofilaments (≈10 nm) form the neuronal cytoskeleton, providing structural support to the cell. [4,5] The normal structure and assembled network of NFs is essential for neuronal function, as it has been shown that mutations in NF-L leading to protein aggregation or to a complete absence of protein are related to motor neuron impairment. [6,7] Following processes accompanied by neural damage, NF-L is released in significant amounts into the interstitial fluid and eventually into the cerebrospinal fluid (CSF) and blood, reaching abnormal levels. Therefore, CSF and blood NF-L levels could be used as a direct marker of neuronal damage, providing an indication of axonal injury, axonal loss, and neuronal death. [1,4] Neurofilaments are structural scaffolding proteins of the neuronal cytoskeleton.
Upon axonal injury, the neurofilament light chain (NF-L) is released into the interstitial fluid and eventually reaches the cerebrospinal fluid and blood. Therefore, NF-L is emerging as a biomarker of neurological disorders, including neurodegenerative dementia, Parkinson's disease, and multiple sclerosis. It is challenging to quantify NF-L in bodily fluids due to its low levels. This work reports the detection of NF-L in aqueous solutions with an organic electronic device. The biosensor is based on the electrolyte-gated organic field-effect transistor (EGOFET) architecture and can quantify NF-L down to sub-pM levels; thanks to modification of the device gate with anti-NF-L antibodies imparted with potentially controlled orientation. The response is fitted to the Guggenheim-Anderson-De Boer adsorption model to describe NF-L adsorption at the gate/electrolyte interface, to consider the formation of a strongly adsorbed protein layer bound to the antibody and the formation of weakly bound NF-L multilayers, an interpretation which is also backed up by morphological characterization via atomic force microscopy. The label-free, selective, and rapid response makes this EGOFET biosensor a promising tool for the diagnosis and monitoring of neuronal damages through the detection of NF-L in physio-pathological ranges.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/admi.202102341.